Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey

Sag S., Kaderli A. A., YILDIZ A., Gul B. C., ÖZDEMİR B., Baran I., ...Daha Fazla

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, cilt.45, sa.5, ss.415-425, 2017 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5543/tkda.2017.80026
  • Dergi Adı: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.415-425
  • Anahtar Kelimeler: Aquaretic treatment, congestive heart failure, hyponatremia, tolvaptan, REDUCED EJECTION FRACTION, VASOPRESSIN V-2-RECEPTOR ANTAGONIST, EVEREST TRIAL, PROGNOSTIC VALUE, DOUBLE-BLIND, INSIGHTS, REGISTRY, RATIONALE, BLOCKADE, OUTCOMES
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice.